What is Lifesci Capital’s Estimate for CMPS FY2025 Earnings?

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) – Lifesci Capital issued their FY2025 earnings per share (EPS) estimates for COMPASS Pathways in a research note issued to investors on Thursday, February 12th. Lifesci Capital analyst F. Brisebois anticipates that the company will post earnings per share of ($1.66) for the year. Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for COMPASS Pathways’ current full-year earnings is ($2.33) per share. Lifesci Capital also issued estimates for COMPASS Pathways’ Q4 2025 earnings at ($0.47) EPS, Q1 2026 earnings at ($0.47) EPS, Q2 2026 earnings at ($0.43) EPS, Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.48) EPS and FY2026 earnings at ($1.84) EPS.

CMPS has been the topic of several other reports. Royal Bank Of Canada upped their price objective on shares of COMPASS Pathways from $16.00 to $21.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of COMPASS Pathways in a research note on Wednesday, January 21st. Morgan Stanley lifted their price objective on shares of COMPASS Pathways from $10.00 to $11.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. Finally, Compass Point set a $15.00 target price on shares of COMPASS Pathways in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $16.11.

COMPASS Pathways Stock Down 0.7%

CMPS stock opened at $5.81 on Monday. The stock has a fifty day moving average of $6.75 and a 200-day moving average of $5.85. COMPASS Pathways has a fifty-two week low of $2.25 and a fifty-two week high of $8.20. The company has a market capitalization of $557.88 million, a price-to-earnings ratio of -2.14 and a beta of 1.92. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.23 and a current ratio of 1.23.

Hedge Funds Weigh In On COMPASS Pathways

A number of institutional investors have recently added to or reduced their stakes in CMPS. The Manufacturers Life Insurance Company bought a new stake in shares of COMPASS Pathways during the 4th quarter valued at about $96,000. Kalehua Capital Management LLC purchased a new stake in COMPASS Pathways in the fourth quarter valued at approximately $5,656,000. Siren L.L.C. bought a new stake in COMPASS Pathways during the fourth quarter valued at approximately $6,900,000. Conservest Capital Advisors Inc. lifted its position in COMPASS Pathways by 24.6% during the fourth quarter. Conservest Capital Advisors Inc. now owns 25,363 shares of the company’s stock valued at $175,000 after purchasing an additional 5,000 shares during the last quarter. Finally, Brooklyn Investment Group purchased a new position in COMPASS Pathways in the 4th quarter worth approximately $134,000. 46.19% of the stock is currently owned by institutional investors.

COMPASS Pathways Company Profile

COMPASS Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, COMPASS Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.